Intellia Announces First Clinical Evidence From Ongoing Phase 1 Study That Nexiguran Ziclumeran (Nex-Z), an in Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (Attr) Amyloidosis
Intellia宣佈其正在進行的1期研究的首個臨床證據，Nexiguran Ziclumeran（Nex-Z）作爲一種體內CRISPR/Cas9基礎的基因編輯療法，可能對輸送蛋白（Attr）澱粉樣變性症的疾病進展產生有利影響。
